¿Emergencia médica?¿Emergencia? Llame al 911. Salas de emergencias más cercanasEmergencias cercanas

Medicamento con receta

Calcium, magnesium, potassium, and sodium oxybates

Datos oficiales de la FDA, no son consejos

Todo lo que aparece aquí viene de la Administración de Alimentos y Medicamentos de los EE. UU. (FDA): la etiqueta del medicamento, el directorio NDC, Drugs@FDA, los informes de retiros y la lista de escasez. Cada dato indica su fuente y su fecha.

Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.

En una emergencia, llame al 911. Si alguien pudo haber tomado demasiado de un medicamento, llame a la Línea de Ayuda para Envenenamientos (Poison Help): 1‑800‑222‑1222.

Calcium, magnesium, potassium, and sodium oxybates: datos clave

Se usa para
En inglés, según la etiqueta: XYWAV is a central nervous system depressant indicated for the treatment of: • Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. (fuente)
Con receta o sin receta
Con receta (Rx)
Hay genérico
La FDA no indica genérico
Último retiro de la FDA
Ninguno registrado

Fuentes: etiqueta de la FDA (1 de julio de 2025); directorio NDC de la FDA (13 de noviembre de 2026); informes de retiros de la FDA (10 de noviembre de 2026). No es un consejo médico.

Respuestas rápidas

¿Para qué se usa Calcium, magnesium, potassium, and sodium oxybates?
La etiqueta aprobada por la FDA (Xywav, Jazz Pharmaceuticals, Inc., 1 de julio de 2025) dice, en inglés: “XYWAV is a central nervous system depressant indicated for the treatment of: • Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. • Idiopathic Hypersomnia (IH) in adults. 1.1 Narcolepsy XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. …” Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Cuáles son los efectos secundarios de Calcium, magnesium, potassium, and sodium oxybates?
La sección «Adverse Reactions» (reacciones adversas) de la etiqueta de la FDA (Xywav, Jazz Pharmaceuticals, Inc., 1 de julio de 2025) comienza así, en inglés: «The following clinically significant adverse reactions appear in other sections of the labeling: • CNS depression [see Warnings and Precautions (5.1)] • Abuse and Misuse [see Warnings and Precautions (5.2)] • Respiratory Depression and Sleep-Disordered Breathing [see Warnings and Precautions (5.4)] • Depression and Suicidality [see Warnings and Precautions (5.5)] • Other Behavioral or Psychiatric Adverse Reactions [see Warnings and Precautions (5.6)] • Parasomnias [see Warnings and Precautions (5.7)] Most common adverse reactions in adults with narcolepsy or IH (≥5%) were nausea, headache, dizziness, anxiety, insomnia, decreased appetite, hyperhidrosis, vomiting, diarrhea, dry mouth, parasomnia, somnolence, fatigue, and tremor (6.1).» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Qué interacciones tiene Calcium, magnesium, potassium, and sodium oxybates?
La sección «Drug Interactions» (interacciones) de la etiqueta de la FDA (Xywav, Jazz Pharmaceuticals, Inc., 1 de julio de 2025) comienza así, en inglés: «• Concomitant use with divalproex sodium: An initial reduction in XYWAV dose of at least 20% is recommended (2.7, 7.2). 7.1 Alcohol, Sedative Hypnotics, and CNS Depressants XYWAV is contraindicated for use in combination with alcohol or sedative hypnotics.» … Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.
¿Calcium, magnesium, potassium, and sodium oxybates tiene una advertencia en recuadro?
Sí. La etiqueta de la FDA de Xywav tiene una advertencia en recuadro, la advertencia más seria de la FDA. Léala en la etiqueta completa y pregunte a su farmacéutico.
¿Hay escasez de Calcium, magnesium, potassium, and sodium oxybates?
La FDA no indica una escasez actual para los productos de este medicamento (datos de la FDA del 13 de noviembre de 2026).
¿Se ha retirado del mercado Calcium, magnesium, potassium, and sodium oxybates?
No aparece ningún retiro vinculado a los productos de este medicamento en los informes de la FDA que usamos.
¿Quién fabrica Calcium, magnesium, potassium, and sodium oxybates?
1 empresa tiene productos con receta de Calcium, magnesium, potassium, and sodium oxybates en el directorio NDC de la FDA, entre ellas Jazz Pharmaceuticals, Inc.

Para qué se usa Calcium, magnesium, potassium, and sodium oxybates

Cita de la sección «Indications and Usage» (indicaciones y uso) de la etiqueta aprobada por la FDA. Se muestra en inglés, tal como la publica la FDA.

XYWAV is a central nervous system depressant indicated for the treatment of: • Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. • Idiopathic Hypersomnia (IH) in adults. 1.1 Narcolepsy XYWAV is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. …

— Etiqueta de la FDA: Xywav, Jazz Pharmaceuticals, Inc., vigente desde el 1 de julio de 2025. Leer la etiqueta completa en DailyMed →

Etiqueta citada: la de la presentación más común (solution, oral), Xywav, Jazz Pharmaceuticals, Inc.; abarca 1 producto del directorio NDC de la FDA. Las citas sobre efectos secundarios, interacciones, dosis y embarazo de abajo vienen de esta misma etiqueta.

Esta página no es un consejo médico. Hable con su médico o farmacéutico antes de empezar, dejar o cambiar cualquier medicamento.

Enfermedades que menciona la etiqueta

Estos nombres aparecen tal cual en la sección «Indications and Usage» de la etiqueta (según una tabla revisada). Cada página muestra los hospitales cuyos sitios web mencionan la enfermedad.

Especialidades médicas relacionadas

Advertencia en recuadro

La advertencia en recuadro («caja negra») es la advertencia más seria de la FDA en la etiqueta de un medicamento, para riesgos graves o mortales.

Esta etiqueta tiene una advertencia en recuadro. Leerla en la etiqueta completa →

Calcium, magnesium, potassium, and sodium oxybates: lo que dice la advertencia en recuadro

Cita de la advertencia en recuadro (Boxed Warning) de la etiqueta aprobada por la FDA. Se muestra en inglés.

WARNING: CENTRAL NERVOUS SYSTEM DEPRESSION and ABUSE AND MISUSE.

  • Central Nervous System Depression XYWAV is a CNS depressant. Clinically significant respiratory depression and obtundation may occur in patients treated with XYWAV at recommended doses [see Warnings and Precautions (5.1, 5.4)].
Leer más de esta sección

Many patients who received XYWAV during clinical trials in narcolepsy and idiopathic hypersomnia were receiving central nervous system stimulants [see Clinical Studies (14.1, 14.2, 14.3)].

  • Abuse and Misuse The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB, either alone or in combination with other CNS depressants, is associated with CNS adverse reactions, including seizure, respiratory depression, decreases in the level of consciousness, coma, and death [see Warnings and Precautions (5.2)]. Because of the risks of CNS depression and abuse and misuse, XYWAV is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the XYWAV and XYREM REMS [see Warnings and Precautions (5.3)]. WARNING: CENTRAL NERVOUS SYSTEM (CNS) DEPRESSION and ABUSE AND MISUSE. See full prescribing information for complete boxed warning. Central Nervous System Depression
  • XYWAV is a CNS depressant, and respiratory depression can occur with XYWAV use (5.1, 5.4) Abuse and Misuse
  • The active moiety of XYWAV is oxybate or gamma-hydroxybutyrate (GHB). Abuse or misuse of illicit GHB is associated with CNS adverse reactions, including seizure, respiratory depression, decreased consciousness, coma, and death (5.2, 9.2) XYWAV is available only through a restricted program called the XYWAV and XYREM REMS (5.3)

— Etiqueta de la FDA: Xywav, Jazz Pharmaceuticals, Inc., vigente desde el 1 de julio de 2025. Leer la etiqueta completa en DailyMed →

Efectos secundarios de Calcium, magnesium, potassium, and sodium oxybates

Cita de la sección «Adverse Reactions» (reacciones adversas) de la etiqueta aprobada por la FDA. Se muestra en inglés. Avise a su médico de cualquier efecto secundario que le preocupe.

The following clinically significant adverse reactions appear in other sections of the labeling:

  • CNS depression [see Warnings and Precautions (5.1)]
  • Abuse and Misuse [see Warnings and Precautions (5.2)]
  • Respiratory Depression and Sleep-Disordered Breathing [see Warnings and Precautions (5.4)]
  • Depression and Suicidality [see Warnings and Precautions (5.5)]
  • Other Behavioral or Psychiatric Adverse Reactions [see Warnings and Precautions (5.6)]
  • Parasomnias [see Warnings and Precautions (5.7)] Most common adverse reactions in adults with narcolepsy or IH (≥5%) were nausea, headache, dizziness, anxiety, insomnia, decreased appetite, hyperhidrosis, vomiting, diarrhea, dry mouth, parasomnia, somnolence, fatigue, and tremor (6.1).
Leer más de esta sección

In a pediatric study with sodium oxybate (same active moiety as XYWAV), the most common adverse reactions (≥5%) were nausea, enuresis, vomiting, headache, weight decreased, decreased appetite, dizziness, and sleepwalking (6.1). To report SUSPECTED ADVERSE REACTIONS, contact Jazz Pharmaceuticals, Inc. at 1-800-520-5568, or FDA at 1-800-FDA-1088 or www.fda.gov/Medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Adult Patients with Narcolepsy The safety of XYWAV was evaluated in a 16‑week double-blind placebo-controlled randomized-withdrawal study in patients with narcolepsy with cataplexy (Study 1), which was followed by an open-label extension phase lasting 24 weeks [see Clinical Studies (14.1)]. Study 1 included an open‑label titration period (OL OTTP), a stable-dose period (SDP), and a double‑blind, placebo‑controlled, randomized-withdrawal period (DB RWP). A total of 201 patients, ages 18 to 70 years, received XYWAV at individually titrated doses for 14 weeks, followed by randomization to XYWAV or matching placebo for 2 weeks of treatment. The mean exposure to XYWAV during this study, including titration, the randomized withdrawal period, and the open-label extension, was 151 days. In patients who remained on treatment, adverse reactions tended to occur early and diminish over time. Adverse Reactions Leading to Treatment Discontinuation in Study 1 In Study 1, 9 of 201 patients (4%) reported adverse reactions that led to withdrawal from the study (anxiety, decreased appetite, depressed mood, depression, fatigue, headache, irritability, nausea, pain in extremity, parasomnia, somnolence, and vomiting). The most common adverse reaction leading to discontinuation was nausea (1.5%). The majority of adverse reactions leading to discontinuation began during the first few weeks of treatment. Commonly Observed Adverse Reactions The most common adverse reactions in Study 1 (incidence ≥5% of XYWAV-treated patients) were headache, nausea, dizziness, decreased appetite, parasomnia, diarrhea, hyperhidrosis, anxiety, and vomiting. Adverse Reactions Occurring at an Incidence of 2% or Greater: Table 4 lists adverse reactions observed in the open-label titration and stable dose periods of Study 1 that occurred at a frequency of 2% or greater in adult patients treated with XYWAV.

— Etiqueta de la FDA: Xywav, Jazz Pharmaceuticals, Inc., vigente desde el 1 de julio de 2025. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Interacciones de Calcium, magnesium, potassium, and sodium oxybates

Cita de la sección «Drug Interactions» (interacciones) de la etiqueta aprobada por la FDA. Se muestra en inglés. Dígale a su farmacéutico todos los medicamentos, vitaminas y productos herbales que toma.

  • Concomitant use with divalproex sodium: An initial reduction in XYWAV dose of at least 20% is recommended (2.7, 7.2). 7.1 Alcohol, Sedative Hypnotics, and CNS Depressants XYWAV is contraindicated for use in combination with alcohol or sedative hypnotics.
Leer más de esta sección

Use of other CNS depressants may potentiate the CNS-depressant effects of XYWAV [see Warnings and Precautions (5.1)]. 7.2 Divalproex Sodium Concomitant use of sodium oxybate with divalproex sodium results in an increase in systemic exposure to GHB, which was shown to cause a greater impairment on some tests of attention and working memory in a clinical study [see Clinical Pharmacology (12.3)]. A similar increase in exposure is expected with concomitant use of XYWAV and divalproex sodium; therefore, an initial dose reduction of XYWAV is recommended when used concomitantly with divalproex sodium [see Dosage and Administration (2.7)]. Prescribers are advised to monitor patient response closely and adjust dose accordingly if concomitant use of XYWAV and divalproex sodium is warranted.

— Etiqueta de la FDA: Xywav, Jazz Pharmaceuticals, Inc., vigente desde el 1 de julio de 2025. Leer la etiqueta completa en DailyMed →

Dosis de Calcium, magnesium, potassium, and sodium oxybates

Cita de la sección «Dosage and Administration» (dosis y administración) de la etiqueta aprobada por la FDA. Se muestra en inglés. Su dosis es la que le receta su médico: no la cambie por su cuenta.

See Full Prescribing Information for complete dosing instructions (2.1 - 2.7). Dosage for Adult Patients with Narcolepsy

  • Initiate dosage at 4.5 g per night orally, divided into two doses (2.1).
  • Titrate to effect in increments of up to 1.5 g per night per week (2.1).
  • Recommended dosage range: 6 g to 9 g per night orally, divided into two doses (2.1).
Leer más de esta sección
  • Doses may be divided equally or unequally and the first dose taken at bedtime and the second dose taken 2.5 to 4 hours later (2.1). Dosage for Pediatric Patients with Narcolepsy (7 Years of Age and Older)
  • The recommended starting dosage, titration regimen, and maximum total nightly dosage are based on body weight (2.2). Dosage for Adult Patients with Idiopathic Hypersomnia
  • XYWAV can be administered as a twice or once nightly regimen in adults (2.3).
  • Twice nightly: Initiate dosage at 4.5 g or less per night orally, divided into two doses. Titrate to effect in increments of up to 1.5 g per night per week, up to 9 g total nightly dose (2.3).
  • Once nightly: Initiate dosage at 3 g or less per night orally, as one dose. Titrate to effect in increments of up to 1.5 g per night per week, up to 6 g total nightly dose (2.3). Important Administration Information
  • Administer XYWAV at least 2 hours after eating (2.4).
  • Prepare XYWAV prior to bedtime; dilute with approximately ¼ cup of water in pharmacy-provided containers (2.4).
  • Take XYWAV while in bed and lie down after dosing (2.4). For Patients Transitioning from Xyrem to XYWAV: Initiate at the same dose and regimen as Xyrem (gram for gram). Titrate as needed based on efficacy and tolerability (2.5). Patients with Hepatic Impairment Recommended starting dosage is one-half of the original dosage per night administered orally, divided into two doses (2.6). 2.1 Dosing Information in Adult Patients with Narcolepsy The recommended starting dosage is 4.5 grams (g) per night administered orally, divided into two doses: 2.25 g at bedtime and 2.25 g taken 2.5 to 4 hours later (see Table 1). Increase the dosage by up to 1.5 g per night per week (e.g., 0.75 g at bedtime and 0.75 g taken 2.5 to 4 hours later), to the recommended dosage range of 6 g to 9 g per night. The dosage may be gradually titrated based on efficacy and tolerability. Some patients may achieve better responses with unequal doses at bedtime and 2.5 to 4 hours later. Doses higher than 9 g per night have not been studied and ordinarily should not be administered. Table 1: Recommended Adult XYWAV Dosage Regimen (g = grams) Note: Some patients may achieve better responses with unequal nightly doses at bedtime and 2.5 to 4 hours later. If a Patient’s Total Nightly Dosage Is: Take at Bedtime: Take 2.5 to 4 Hours Later: 4.5 g per night 2.25 g 2.25 g 6 g per night 3 g 3 g 7.5 g per night 3.75 g 3.75 g 9 g per night 4.5 g 4.5 g 2.2 Dosing Information in Pediatric Patients with Narcolepsy For pediatric patients 7 years of age and older, XYWAV is administered orally twice per night. The recommended starting pediatric dosage, titration regimen, and maximum total nightly dosage are based on patient weight, as specified in Table 2.

— Etiqueta de la FDA: Xywav, Jazz Pharmaceuticals, Inc., vigente desde el 1 de julio de 2025. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Calcium, magnesium, potassium, and sodium oxybates en el embarazo

Cita de la parte sobre embarazo (Pregnancy) de la etiqueta aprobada por la FDA. Se muestra en inglés. Pregunte a su médico antes de tomar cualquier medicamento si está embarazada o planea estarlo.

Risk Summary There are no adequate data on the developmental risk associated with the use of XYWAV or sodium oxybate in pregnant women.

Leer más de esta sección

Oral administration of sodium oxybate to pregnant rats (0, 150, 350, or 1,000 mg/kg/day) or rabbits (0, 300, 600, or 1,200 mg/kg/day) throughout organogenesis produced no clear evidence of developmental toxicity; however, oral administration to rats throughout pregnancy and lactation resulted in increased stillbirths and decreased offspring postnatal viability and growth, at a clinically relevant dose [see Data]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Labor or Delivery XYWAV has not been studied in labor or delivery. In obstetric anesthesia using an injectable formulation of sodium oxybate, newborns had stable cardiovascular and respiratory measures but were very sleepy, causing a slight decrease in Apgar scores. There was a fall in the rate of uterine contractions 20 minutes after injection. Placental transfer is rapid, and gamma-hydroxybutyrate (GHB) has been detected in newborns at delivery after intravenous administration of GHB to mothers. Subsequent effects of sodium oxybate on later growth, development, and maturation in humans are unknown. Data Animal Data Oral administration of sodium oxybate to pregnant rats (0, 150, 350, or 1,000 mg/kg/day) or rabbits (0, 300, 600, or 1,200 mg/kg/day) throughout organogenesis produced no clear evidence of developmental toxicity. The highest doses of sodium oxybate tested in rats and rabbits were approximately 1 and 3 times, respectively, the maximum recommended human dose (MRHD) of 9 g per night on a body surface area (mg/m 2) basis. Additionally, oral administration of sodium oxybate (0, 150, 350, or 1,000 mg/kg/day) to rats throughout pregnancy and lactation resulted in increased stillbirths and decreased offspring postnatal viability and body weight gain at the highest dose tested. The no-effect dose for pre- and post-natal developmental toxicity in rats is less than the MRHD on a mg/m 2 basis.

— Etiqueta de la FDA: Xywav, Jazz Pharmaceuticals, Inc., vigente desde el 1 de julio de 2025. Leer la etiqueta completa en DailyMed →

Cuándo no se debe usar Calcium, magnesium, potassium, and sodium oxybates

Cita de la sección «Contraindications» (contraindicaciones) de la etiqueta aprobada por la FDA. Se muestra en inglés.

XYWAV is contraindicated for use in:

  • combination with sedative hypnotics [see Warnings and Precautions (5.1)].
  • combination with alcohol [see Warnings and Precautions (5.1, 5.2)].
  • patients with succinic semialdehyde dehydrogenase deficiency [see Clinical Pharmacology (12.3)].
  • In combination with sedative hypnotics or alcohol (4)
  • Succinic semialdehyde dehydrogenase deficiency (4)

— Etiqueta de la FDA: Xywav, Jazz Pharmaceuticals, Inc., vigente desde el 1 de julio de 2025. Leer la etiqueta completa en DailyMed →

Sobredosis de Calcium, magnesium, potassium, and sodium oxybates

Cita de la sección «Overdosage» (sobredosis) de la etiqueta aprobada por la FDA. Se muestra en inglés. Si alguien pudo haber tomado demasiado, llame a Poison Help al 1-800-222-1222 (o al 911 en una emergencia).

Human Experience Information regarding overdose with XYWAV is derived largely from reports in the medical literature that describe symptoms and signs in individuals who have ingested GHB illicitly. In these circumstances the co-ingestion of other drugs and alcohol was common, and may have influenced the presentation and severity of clinical manifestations of overdose. In adult clinical trials with Xyrem (same active moiety as XYWAV), two cases of overdose were reported.

Leer más de esta sección

In the first case, an estimated dose of 150 g, more than 15 times the maximum recommended dose, caused a patient to be unresponsive with brief periods of apnea and to be incontinent of urine and feces. This individual recovered without sequelae. In the second case, death was reported following a multiple drug overdose consisting of Xyrem and numerous other drugs. No cases of overdose (greater than 9 g) with XYWAV were reported in the XYWAV clinical trials. 10.2 Signs and Symptoms Information about signs and symptoms associated with overdosage with XYWAV derives from reports of illicit use of GHB. Patient presentation following overdose is influenced by the dose ingested, the time since ingestion, the co-ingestion of other drugs and alcohol, and the fed or fasted state. Patients have exhibited varying degrees of depressed consciousness that may fluctuate rapidly between a confusional, agitated combative state with ataxia and coma. Emesis (even when obtunded), diaphoresis, headache, and impaired psychomotor skills have been observed. No typical pupillary changes have been described to assist in diagnosis; pupillary reactivity to light is maintained. Blurred vision has been reported. An increasing depth of coma and acidosis have been observed at higher doses. Myoclonus and tonic-clonic seizures have been reported. Respiration may be unaffected or compromised in rate and depth. Cheyne-Stokes respiration and apnea have been observed. Bradycardia and hypothermia may accompany unconsciousness, as well as muscular hypotonia, but tendon reflexes remain intact. 10.3 Recommended Treatment of Overdose General symptomatic and supportive care should be instituted immediately, and gastric decontamination may be considered if co-ingestants are suspected. Because emesis may occur in the presence of obtundation, appropriate posture (left lateral recumbent position) and protection of the airway by intubation may be warranted. Although the gag reflex may be absent in deeply comatose patients, even unconscious patients may become combative to intubation, and rapid-sequence induction (without the use of sedative) should be considered. Vital signs and consciousness should be closely monitored. The bradycardia reported with GHB overdose has been responsive to atropine intravenous administration. No reversal of the central depressant effects of XYWAV can be expected from naloxone or flumazenil administration.

— Etiqueta de la FDA: Xywav, Jazz Pharmaceuticals, Inc., vigente desde el 1 de julio de 2025. Esto es solo una parte de la sección. Leer la etiqueta completa en DailyMed →

Presentaciones y vía de administración

Formas farmacéuticasSolución
VíaOral
Productos con receta1 en el directorio NDC de la FDA
Nombres de marcaXywav

Empresas que tienen este medicamento

Empresas en el directorio NDC de la FDA: la empresa que aparece en el envase (fabricante o distribuidor), con su número de productos con receta.

Historial de aprobación de la FDA

  • NDA: Solicitud de nuevo medicamento (NDA): así se aprueba un medicamento nuevo, normalmente de marca.
Solicitudes de marca y biológicas
SolicitudPatrocinadorAprobadaCambios aprobados después
NDA212690
XYWAV
Jazz21 de julio de 2020 13, el último 28 de julio de 2025
2025: REMS · 2025: REMS · 2024: REMS

Escasez

La lista de escasez de la FDA no incluye estos productos.

Base de datos de escasez de medicamentos de la FDA →

Retiros del mercado

No aparece ningún retiro vinculado a estos productos (por su código NDC) en los informes de la FDA.

Identificadores oficiales

RxCUI (RxNorm)2393794, 2393795
ID (SPL set ID) de la etiqueta citada1e0ae43a-037f-42af-8e23-a0e51d75abe8
Etiquetas de la FDA (SPL)1
Solicitudes de la FDANDA212690
Principios activos (FDA)CALCIUM OXYBATE / MAGNESIUM OXYBATE / POTASSIUM OXYBATE / SODIUM OXYBATE

Siguientes pasos

Fuentes

  1. Etiqueta aprobada por la FDA en DailyMed (Biblioteca Nacional de Medicina) — Xywav, Jazz Pharmaceuticals, Inc., vigente desde el 1 de julio de 2025; vía openFDA, datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  2. NDC Directory (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  3. Drugs@FDA (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026
  4. Drug recall enforcement reports (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 10 de noviembre de 2026, consultados el 14 de noviembre de 2026
  5. Drug shortages (openFDA) — Administración de Alimentos y Medicamentos de los EE. UU. (FDA), datos de la FDA exportados el 13 de noviembre de 2026, consultados el 14 de noviembre de 2026

La FDA ofrece los datos de openFDA tal cual; pueden estar incompletos. Guíese siempre por la etiqueta que viene con su medicamento. Buscador de informes de retiros de la FDA →

Informar un error → · Información para fabricantes de medicamentos